Single User License
INR 133500
Site License
INR 267000
Corporate User License
INR 400500

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Malignant Pleural Mesothelioma-Pipeline Review, H1 2015

Malignant Pleural Mesothelioma-Pipeline Review, H1 2015

  Request for Sample Report

Executive Summary

Malignant Pleural Mesothelioma-Pipeline Review, H1 2015


Global Markets Direct's, 'Malignant Pleural Mesothelioma-Pipeline Review, H1 2015', provides an overview of the Malignant Pleural Mesothelioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Malignant Pleural Mesothelioma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Malignant Pleural Mesothelioma Overview 10

Therapeutics Development 11

Pipeline Products for Malignant Pleural Mesothelioma-Overview 11

Pipeline Products for Malignant Pleural Mesothelioma-Comparative Analysis 12

Malignant Pleural Mesothelioma-Therapeutics under Development by Companies 13

Malignant Pleural Mesothelioma-Therapeutics under Investigation by Universities/Institutes 15

Malignant Pleural Mesothelioma-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Malignant Pleural Mesothelioma-Products under Development by Companies 19

Malignant Pleural Mesothelioma-Products under Investigation by Universities/Institutes 22

Malignant Pleural Mesothelioma-Companies Involved in Therapeutics Development 23

Aduro BioTech, Inc. 23

Advantagene, Inc. 24

Amphera BV 25

Bayer AG 26

Biogen, Inc. 27

Bionomics Limited 28

Boehringer Ingelheim GmbH 29

Boston Biomedical, Inc. 30

Bristol-Myers Squibb Company 31

CanBas Co., Ltd. 32

Concordia Healthcare Corp. 33

EnGeneIC Ltd 34

F. Hoffmann-La Roche Ltd. 35

Five Prime Therapeutics, Inc. 36

Genelux Corporation 37

GlaxoSmithKline plc 38

Juno Therapeutics Inc. 39

MedImmune, LLC 40

Merck & Co., Inc. 41

MolMed S.p.A. 42

Morphotek, Inc. 43

Novartis AG 44

Oxford BioMedica plc 45

Pfizer Inc. 46

Pharma Mar, S.A. 47

Polaris Pharmaceuticals, Inc. 48

Synta Pharmaceuticals Corp. 49

Verastem, Inc. 50

Virttu Biologics Limited 51

Malignant Pleural Mesothelioma-Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Target 53

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

amatuximab-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

anetumab ravtansine-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

ascrinvacumab-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

BG-00001-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

BMS-986148-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

BNC-105-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

CBP-501-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Cell Therapy 1 for Oncology-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

CRS-207-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

defactinib hydrochloride-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

FP-1039-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

ganetespib-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Gene Therapy for Malignant Pleural Mesothelioma-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

GLONC-1-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

GSK-2256098-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

HSV-1716-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

iCasp9M28z-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

JTCR-016-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

MesoCancerVac-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

MesoCART-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Monoclonal Antibody Conjugated to Target Mesothelin for Oncology-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

napabucasin-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

NGR-hTNF-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

nintedanib-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

pegargiminase-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

pembrolizumab-Drug Profile 111

Product Description 111

Mechanism of Action 111

R&D Progress 111

porfimer sodium-Drug Profile 118

Product Description 118

Mechanism of Action 118

R&D Progress 118

RG-7787-Drug Profile 119

Product Description 119

Mechanism of Action 119

R&D Progress 119

Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer-Drug Profile 120

Product Description 120

Mechanism of Action 120

R&D Progress 120

TargomiRs-Drug Profile 121

Product Description 121

Mechanism of Action 121

R&D Progress 121

trabectedin-Drug Profile 123

Product Description 123

Mechanism of Action 123

R&D Progress 123

tremelimumab-Drug Profile 127

Product Description 127

Mechanism of Action 127

R&D Progress 127

TroVax-Drug Profile 129

Product Description 129

Mechanism of Action 129

R&D Progress 129

Vaccine For Oncolytic Newcastle Disease Virus-Drug Profile 132

Product Description 132

Mechanism of Action 132

R&D Progress 132

VS-5584-Drug Profile 133

Product Description 133

Mechanism of Action 133

R&D Progress 133

Malignant Pleural Mesothelioma-Recent Pipeline Updates 135

Malignant Pleural Mesothelioma-Dormant Projects 187

Malignant Pleural Mesothelioma-Discontinued Products 188

Malignant Pleural Mesothelioma-Product Development Milestones 189

Featured News & Press Releases 189

May 14, 2015: PharmaMar announces new advances in oncology at ASCO 2015 for its compound YONDELIS in small cell lung cancer, soft tissue sarcoma, and mesothelioma 189

Apr 23, 2015: Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation from FDA, Baron & Budd Reports 190

Apr 19, 2015: Early Findings with KEYTRUDA (pembrolizumab), Merck's Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting 190

Apr 19, 2015: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients 191

Mar 26, 2015: Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma 192

Mar 18, 2015: New Data Investigating Merck's KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015 192

Jan 20, 2015: Verastem Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 194

Jan 20, 2015: Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma 194

Dec 18, 2014: Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma 195

Oct 24, 2014: Verastem Presents New Data on Mesothelioma Programs at the 12th International Mesothelioma Interest Group Meeting 195

Appendix 198

Methodology 198

Coverage 198

Secondary Research 198

Primary Research 198

Expert Panel Validation 198

Contact Us 198

Disclaimer 199

List of Tables

Number of Products under Development for Malignant Pleural Mesothelioma, H1 2015 11

Number of Products under Development for Malignant Pleural Mesothelioma-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Development by Companies, H1 2015 (Contd..2) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Malignant Pleural Mesothelioma-Pipeline by Aduro BioTech, Inc., H1 2015 23

Malignant Pleural Mesothelioma-Pipeline by Advantagene, Inc., H1 2015 24

Malignant Pleural Mesothelioma-Pipeline by Amphera BV, H1 2015 25

Malignant Pleural Mesothelioma-Pipeline by Bayer AG, H1 2015 26

Malignant Pleural Mesothelioma-Pipeline by Biogen, Inc., H1 2015 27

Malignant Pleural Mesothelioma-Pipeline by Bionomics Limited, H1 2015 28

Malignant Pleural Mesothelioma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 29

Malignant Pleural Mesothelioma-Pipeline by Boston Biomedical, Inc., H1 2015 30

Malignant Pleural Mesothelioma-Pipeline by Bristol-Myers Squibb Company, H1 2015 31

Malignant Pleural Mesothelioma-Pipeline by CanBas Co., Ltd., H1 2015 32

Malignant Pleural Mesothelioma-Pipeline by Concordia Healthcare Corp., H1 2015 33

Malignant Pleural Mesothelioma-Pipeline by EnGeneIC Ltd, H1 2015 34

Malignant Pleural Mesothelioma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 35

Malignant Pleural Mesothelioma-Pipeline by Five Prime Therapeutics, Inc., H1 2015 36

Malignant Pleural Mesothelioma-Pipeline by Genelux Corporation, H1 2015 37

Malignant Pleural Mesothelioma-Pipeline by GlaxoSmithKline plc, H1 2015 38

Malignant Pleural Mesothelioma-Pipeline by Juno Therapeutics Inc., H1 2015 39

Malignant Pleural Mesothelioma-Pipeline by MedImmune, LLC, H1 2015 40

Malignant Pleural Mesothelioma-Pipeline by Merck & Co., Inc., H1 2015 41

Malignant Pleural Mesothelioma-Pipeline by MolMed S.p.A., H1 2015 42

Malignant Pleural Mesothelioma-Pipeline by Morphotek, Inc., H1 2015 43

Malignant Pleural Mesothelioma-Pipeline by Novartis AG, H1 2015 44

Malignant Pleural Mesothelioma-Pipeline by Oxford BioMedica plc, H1 2015 45

Malignant Pleural Mesothelioma-Pipeline by Pfizer Inc., H1 2015 46

Malignant Pleural Mesothelioma-Pipeline by Pharma Mar, S.A., H1 2015 47

Malignant Pleural Mesothelioma-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 48

Malignant Pleural Mesothelioma-Pipeline by Synta Pharmaceuticals Corp., H1 2015 49

Malignant Pleural Mesothelioma-Pipeline by Verastem, Inc., H1 2015 50

Malignant Pleural Mesothelioma-Pipeline by Virttu Biologics Limited, H1 2015 51

Assessment by Monotherapy Products, H1 2015 52

Number of Products by Stage and Target, H1 2015 54

Number of Products by Stage and Mechanism of Action, H1 2015 56

Number of Products by Stage and Route of Administration, H1 2015 58

Number of Products by Stage and Molecule Type, H1 2015 60

Malignant Pleural Mesothelioma Therapeutics-Recent Pipeline Updates, H1 2015 135

Malignant Pleural Mesothelioma-Dormant Projects, H1 2015 187

Malignant Pleural Mesothelioma-Discontinued Products, H1 2015 188

List of Figures

Number of Products under Development for Malignant Pleural Mesothelioma, H1 2015 11

Number of Products under Development for Malignant Pleural Mesothelioma-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 17

Assessment by Monotherapy Products, H1 2015 52

Number of Products by Top 10 Targets, H1 2015 53

Number of Products by Stage and Top 10 Targets, H1 2015 53

Number of Products by Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Top 10 Routes of Administration, H1 2015 57

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 58

Number of Products by Top 10 Molecule Types, H1 2015 59

Number of Products by Stage and Top 10 Molecule Types, H1 2015 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Aduro BioTech, Inc.

Advantagene, Inc.

Amphera BV

Bayer AG

Biogen, Inc.

Bionomics Limited

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

CanBas Co., Ltd.

Concordia Healthcare Corp.

EnGeneIC Ltd

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Genelux Corporation

GlaxoSmithKline plc

Juno Therapeutics Inc.

MedImmune, LLC

Merck & Co., Inc.

MolMed S.p.A.

Morphotek, Inc.

Novartis AG

Oxford BioMedica plc

Pfizer Inc.

Pharma Mar, S.A.

Polaris Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

Verastem, Inc.

Virttu Biologics Limited

Malignant Pleural Mesothelioma Therapeutic Products under Development, Key Players in Malignant Pleural Mesothelioma Therapeutics, Malignant Pleural Mesothelioma Pipeline Overview, Malignant Pleural Mesothelioma Pipeline, Malignant Pleural Mesothelioma Pipeline Assessment

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]